Financial Performance - For the year ended December 31, 2025, the company reported revenue of RMB 551.1 million, an increase of 114.2% compared to RMB 257.2 million in 2024[5] - Gross profit for the same period was RMB 266.6 million, representing a 209.2% increase from RMB 86.2 million in 2024[5] - The company reduced its pre-tax loss to RMB 254.1 million, a 60.7% improvement from a loss of RMB 647.1 million in the previous year[7] - Adjusted net loss for the year was RMB 165.0 million, down 65.8% from RMB 482.6 million in 2024[5] - The company reported a basic and diluted loss per share of RMB 0.24, a reduction of 63.6% from RMB 0.66 in 2024[5] - The group reported a pre-tax loss of RMB 19,809,000 for 2025, a decrease from RMB 21,639,000 in 2024[27] - The adjusted net loss for the year ended December 31, 2025, was RMB 164.99 million, a significant improvement from the adjusted net loss of RMB 482.61 million in 2024[113] Revenue Growth - The group's revenue for 2025 reached RMB 551,069,000, a significant increase of 114.3% compared to RMB 257,249,000 in 2024[20] - Revenue from the sale of surgical robot systems, instruments, and accessories amounted to RMB 539,267,000, up from RMB 252,410,000 in the previous year, reflecting a growth of 113.5%[20] - The company achieved significant growth in overseas markets, with new overseas orders exceeding 100 units and sales revenue in these markets increasing fivefold compared to the previous year[5] - The group’s revenue from overseas customers was RMB 400,230,000 in 2025, a substantial increase from RMB 103,524,000 in 2024, representing a growth of 286.5%[25] - The company reported revenue of RMB 551.1 million, a significant increase of 114% from RMB 257.2 million in the previous year, with overseas market revenue accounting for 73% of total revenue[56] Operational Efficiency - The company focused on core product development, leading to a decrease in operating expenses and improved operational efficiency[7] - Free cash flow for the year was a net outflow of RMB 63 million, an improvement from a net outflow of RMB 388 million in 2024[7] - Sales and marketing expenses decreased to RMB 203.6 million for the year ending December 31, 2025, from RMB 207.9 million in the previous year, with the expense ratio dropping from 80.8% to 36.9% of revenue[104] - Research and development costs decreased by 30.0% to RMB 216.0 million for the year ending December 31, 2025, down from RMB 308.7 million in the previous year, reflecting a focus on high-value projects[106] Assets and Liabilities - Total assets as of December 31, 2025, were RMB 1,035.6 million, compared to RMB 856.5 million in 2024[12] - The company's equity attributable to shareholders increased to RMB 410.7 million from RMB 278.2 million in the previous year[13] - The company's interest-bearing borrowings decreased to RMB 389.05 million in 2025 from RMB 634.54 million in 2024, with a significant portion due within one year[39] - The asset-liability ratio improved to 70.0% as of December 31, 2025, compared to 80.0% in 2024[123] - The company's cash and cash equivalents increased to RMB 636.3 million as of December 31, 2025, up from RMB 612.2 million in 2024, primarily due to the completion of an H-share placement[120] Market Opportunities - The global surgical robot market is projected to grow from $7.7 billion in 2019 to $21.2 billion by 2024, with a compound annual growth rate (CAGR) of 22.4%[49] - By 2033, the global market size is expected to reach $84.2 billion, with a CAGR of 16.6%[49] - In China, the penetration rate of robotic-assisted surgeries is relatively low, indicating significant growth potential driven by population size and increasing health awareness[49] - The Chinese surgical robot market is experiencing rapid growth, with overseas sales becoming a core incremental space for the industry[49] Innovation and Development - The company has launched its independently developed UniPath™ electronic bronchoscope surgical navigation system, increasing the number of approved surgical robot products to seven, making it the first and only company to commercialize products across all five major surgical robot tracks[64] - The company has established a strong presence in top-tier hospitals, with over 90% of installations in Class A hospitals in China[69] - The company has developed the world's first and only commercial remote surgery system that covers all departments and surgical procedures, achieving a 100% success rate in nearly 800 remote clinical surgeries globally[73] - The company has established a comprehensive supply chain system in China, with two production bases located in Shanghai and Suzhou, enabling large-scale production capabilities for multiple surgical robot products[95] Corporate Governance - The audit committee consists of two independent non-executive directors and one non-executive director, focusing on financial reporting and risk management effectiveness[145] - The company aims to enhance its corporate governance practices to ensure compliance with the corporate governance code[144] - The company has complied with all applicable laws and regulations in all material respects during the reporting period[148] Future Plans - The company plans to continue global resource integration and expansion, focusing on multi-disciplinary clinical applications and remote technology innovations[70] - The company plans to allocate 40% of the net proceeds from the June 2024 placement for core business development and ecosystem layout, including overseas product registration and necessary R&D improvements[127] - The company intends to use 70% of the net proceeds from the December 2024 placement for core business development and 30% for operational funding and general corporate purposes[130]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 董事會會議召開日期 上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合稱「本集 團」）董事會（「董事會」）茲通告，本公司謹定於2026年3月26日（星期四）舉行董 事會會議，以考慮及通過（其中包括）本集團截至2025年12月31日止年度的全年 業績及公佈，建議之末期股息（如有），以及處理其他事項。 承董事會命 上海微創醫療機器人（集團）股份有限公司 主席 常兆華博士 中國上海，2026年3月16日 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 於本公告日期，執行董事為何超博士及劉雨先生；非執行董事為常兆華博士、白藤泰司先 生、蘆田典裕先生、陳琛先生及梁敏女士；以及獨立非執行董事為劉國恩博士、周嘉鴻先生、 姚海嵩先生及鍾偉文先生。 ...

Summary of the Conference Call for MicroPort Robotics Company Overview - **Company**: MicroPort Robotics - **Industry**: Surgical Robotics Key Points Revenue Growth and Projections - MicroPort Robotics is entering a revenue explosion phase, with expected growth from zero to 560 million CNY from 2021 to 2025 [2] - Anticipated continued high growth in 2026, with a potential break-even point in 2027 [2] Research and Development - R&D expenses peaked in 2022 and are now on a downward trend as the product matrix becomes more complete [2] - The focus is shifting towards commercialization and global expansion [2] - R&D expenses are expected to decrease from 2023 to 2025, reflecting a more complete product layout and progress in commercialization [3] Market Dynamics - The overseas market is becoming a core growth driver, with export growth expected to surpass domestic growth by 2025 [2] - Anticipated overseas orders in 2026 are projected to reach between 120 to 200 units, with a 5-year compound annual growth rate (CAGR) of 25% to 30% [2][20] Competitive Landscape - Domestic market share of the Da Vinci system has decreased from 67% to over 40% due to accelerated domestic alternatives [2] - MicroPort's "TUMAI" series is closing the technology gap with Da Vinci, reducing the time lag to 5 years [2] Policy Environment - Positive policy changes are expected, with a faster issuance of registration certificates by 2025 and an increase in medical insurance coverage in Beijing and Shanghai to 60%-80% [2][8] - The price of surgeries is projected to decrease to 20,000-30,000 CNY, which will encourage more procedures to be covered by insurance [11] Clinical Value of Robotic Surgery - Robotic surgery enhances visualization and precision, reducing the surgeon's physical burden and potentially extending their careers [4] - The technology allows for remote operations, addressing the uneven distribution of medical resources [4] Market Size and Trends - The global surgical robotics market is expected to reach approximately 20 billion USD by 2024, with laparoscopic surgical robots accounting for nearly 50% of this market [5] - The penetration rate of laparoscopic surgical robots in the U.S. is projected to be around 22% by 2024, while in China, it is currently less than 1% [6] Pricing and Competition - The price of the Da Vinci system is around 18 million CNY, while domestic alternatives range from 10 million to 13 million CNY [7] - Increased competition is expected as more domestic brands enter the market, with a focus on competitive bidding prices [7] Future Outlook - The company expects a significant increase in overseas orders in 2026, with a baseline expectation of 120 units and a potential for 200 units based on recent order trends [20] - Long-term growth is projected to maintain a CAGR of over 50%, with profitability expected by 2027 [21] Challenges and Opportunities - The transition from project approval to insurance coverage remains challenging, dependent on procedure maturity and local insurance capabilities [11] - The increasing number of domestic manufacturers and competitive pricing may facilitate broader insurance coverage in the future [11] Product Strategy - The TUMAI series combines multi-port, single-port, and 5G remote surgery capabilities to offer diverse configurations [15] - The company is also expanding into orthopedic robotics and natural orifice robots, with the latter expected to see limited initial uptake [18] Conclusion - MicroPort Robotics is positioned for significant growth in the surgical robotics market, driven by innovative product offerings, favorable policy changes, and an expanding global market presence [2][20][21]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分 ...

Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 內幕消息公告 聯交所就本公司H股全流通授出上市批准 本公告乃上海微創醫療機器人（集團）股份有限公司（「本公司」）根據香港聯合 交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及證券 及期貨條例（香港法例第571章）第XIVA部（「內幕消息條例」）作出。 茲提述本公司日期為2026年2月4日的公告（「該公告」），內容有關本公司就申請 建議實行H股全流通獲中國證券監督管理委員會發出備案通知書。除另有說明 外，本公告所用詞彙與該公告所界定者具有相同涵義。 聯交所授出上市批准 本公司董事會宣佈，本公司已收到聯交所授出日期為2026年2月13日就5,989,798 股H股（「轉換H ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，截至本公告日，本集團核心產品圖邁®腔 鏡手術機器人（「圖邁」）全球商業化訂單突破200台，覆蓋近50個國家和地區， 已完成商業化裝機近130台。圖邁商業化訂單和裝機規模的再次里程碑式躍升， 標誌著其臨床價值在全球範圍內獲得持續、廣泛的認可，是對圖邁安全性、穩 定性、可靠性的系統性認證。來自不同國家、不同醫療體系、不同專科背景的 外科醫生，正在以真實而審慎的臨床決策，將圖邁納入日常手術實踐與長期學 科建設之中。 在已覆蓋的近50個國家和地區中，訂單數超5台的達12個，新興市場代表印度、 巴西、阿根廷增長強勁，其中印度累計訂單已達14台，巴西超過10台；發達國 家市場持續突破，西班牙、澳大利亞等國家成為快速增長點。圖邁商業化已在 全球範圍內形成多區域協同共振的新格局，貫穿發展中國家新興市場以及發 達國家成熟醫療體系。 （於中華人民共和國註冊成立的股份有限公司） – 1 – ...

Investment Rating - The investment rating for the company is "Buy" [1][10]. Core Insights - The surgical robot industry has a broad prospect with high clinical value, driven by both industry and policy [4][5]. - The domestic industry is at a pivotal moment, with increasing approval of domestic surgical robots and a growing number of local brands [4][5][6]. - The company is a leading player in the domestic surgical robot market, with a rich product portfolio and positive clinical feedback [7][8]. Summary by Sections Company Overview - The company, Shanghai MicroPort Medical Robotics, focuses on the design, development, and commercialization of surgical robots, aiming to assist surgeons in complex surgeries [17]. - Established in 2014, the company has developed a platform for innovation and industrialization in surgical robots, with multiple products approved for clinical use [18][20]. Market Potential - The global surgical robot market is expected to grow significantly, with a projected market size of $21.2 billion by 2024, reflecting a compound annual growth rate (CAGR) of 22.4% from $7.7 billion in 2019 [42]. - The laparoscopic surgical robot segment is the largest, accounting for over 50% of the total market [42]. Product Portfolio - The company has a diverse range of products, including the TUMAI laparoscopic surgical robot series and the Honghu orthopedic surgical robot series, with a total of seven commercialized products [8][20]. - The TUMAI series has been recognized in over 40 countries and regions, achieving significant sales and installations [8]. Financial Projections - Revenue is expected to reach RMB 569 million, RMB 896 million, and RMB 1.308 billion in 2025, 2026, and 2027, respectively, with year-on-year growth rates of 121%, 57%, and 46% [9][12]. - The company is projected to narrow its losses significantly, with a forecasted net profit of RMB 530 million by 2027 [9][12]. Competitive Landscape - The domestic market is seeing an increase in competition, with 11 local brands now approved for surgical robots, indicating a shift towards domestic alternatives to established international brands [5][53]. - The company maintains a competitive edge through its advanced technology and product offerings, which are well-received in both domestic and international markets [6][8].

致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） – 1 – | | | 於本公告日期 | | --- | --- | --- | | | | 佔本公司 | | | 將轉換為 | 已發行股本 | | | H股的非上市 | 總額的概約 | | 股東姓名 | 股份數目 | 附註 百分比 | | 上海潤昆天祿企業管理中心（有限合夥） | 589,806 | 0.0572% | | 深圳芯龍投資合夥企業（有限合夥） | 5,399,992 | 0.5236% | | 總計 | 5,989,798 | 0.5808% | 附註： 於本公告日期，本公司已發行合共1,031,330,331股股份，包括6,599,543股非上市股份及 1,024,730,788股H股。 於本公告日期，本公司有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 自願性公告 本公告由上海微醫療機器人（集團）股份有限公司（「本公司」，連同其附屬公司 統稱為「本集團」）自願作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於 對本集團截至2025年12月31日止年度（「報告期間」）未經審核綜合管理賬目及董 事會現時可獲得數據的初步評估及分析，董事會預期本公司報告期間的收入 較截至2024年12月31日止年度同比增長約110%至120%。該大幅躍升主要歸因於 核心產品圖邁®腔鏡手術機器人（「圖邁」）商業化取得突破性進展，銷售增長迅 猛，尤其是圖邁海外市場拓展成效顯著，全年新簽海外市場訂單逾百台，全年 海外市場銷售收入為去年的五倍以上，增速遠 ...